Nanjing, China 25th October, 2021 — NNB Nutrition (NNB) announced that it has reached a strategic collaboration with GCV Life (GCVL), a first-class healthcare and life science-focused company which works with global innovators and commercializes novel life science solutions in the Asian markets. In the process of active and effective communication between both parties, GCVL acts in the best interest of the Innovator partner for the launch of their innovative products across the region. NNB entrusts GCVL with our finest ingredient "MitoPrime™" to make a hit in the Indian market.
MitoPrime™ is NNB's patented, highly enhanced form of L-ergothioneine, known in the scientific community as the "longevity vitamin". With anti-oxidation capabilities stronger than any other product known to mankind, this unique ingredient is available in multiple formats, including topical cosmetic applications.
Some topical application claims MitoPrime™ can make:
- Reverses Sun Damage
- Improves Smoothness & Luminosity
- Reduction in Pores
- Protects Collagen
- Evens Skin Tone
- Increases Elasticity
- Repairs Skin Mitochondrial Damage
- Protects Skin Cell Membranes
- Removes Wrinkle-causing cells
- Strengthens the Skin Microbes
For more information, please visit the Mio Prime Website
It is confident that GCV Life as a commercialization partner will successfully develop the high-growth Indian market for path-breaking innovation. NNB is looking for cosmetic companies to utilize this ingredient in their formulations to enhance their products’ benefits and become the market leaders in the cosmetics market. If customers are in a company with strong spirit to lead the cosmetics market and an appreciation for science-backed ingredients, get in touch with NNB and NNB make huge difference to the world.
NNB Nutrition is a leading technological enterprise dedicated to research, development, production and sales of high-quality, innovative nutritional and functional food ingredients. Headquartered in Nanjing, China and subsidiaries in California, USA, Shanghai and Hong Kong, NNB has an elite global team of over 100 scientists from more than 10 countries. The team constantly designs and delivers innovative ingredients as well as health solutions to the market driven by mission, which is creating premium products on behalf of the health of mankind.
We are not simply a manufacturer of supplements, what we aim for is bringing completely innovative ingredient ideas from the brain to your life” said Kylin Liao, the founder of NNB. All the members in NNB team keep this mission in mind and pursue unremittingly through the process of concept creation, idea implementation via technology R&D, clinical study, patent filing, flexible manufacturing and marketing. Compared to incorrect claims without any clinical support existing in the industry today, Kylin values technology and believes in the science of innovation, which leads NNB to achieve rapid development in R&D, creating a niche and strong recognition for the company.
In collaboration with outstanding, world-class scientists, NNB has built one of the industry’s top-tier international R&D teams, using customized processing mode to create and produce new raw materials for global partners. In this team, we have "ingredientologist" and biochemist Shawn Wells, also dubbed as the “World’s Greatest Formulator”, as Chief Science Officer. Shawn has formulated more than 500 products and has 10 patents in this industry.
GCV Life (GCVL) is an Investment Banking & Innovation Licensing firm exclusively working in the life science & healthcare industry. Operating for over a decade as an Investment bank, GCVL has closed many deals for Mergers & Acquisitions, Fund Raise & Licensing globally. Under Innovation Licensing, GCVL represents over 15 innovators with Intellectual Property-protected products across pharmaceuticals, nutraceuticals & medical devices for commercializing in India & other emerging markets. GCVL has developed a very unique & differentiated business model that has enabled faster commercialization maximizing return on investment for its Innovation partners.